Anna Palmer Durbin, M.D.

  • Joint Appointment in Medicine
Female

Expertise

Infectious Disease

Research Interests

International health; dengue; malaria; vaccines

Request an Appointment

Insurance Information

Main Phone

Outside of Maryland & Washington D.C.

Request Appointment

International Patients

Request Appointment

Locations

The Johns Hopkins Hospital (Main Entrance)

Appointment Phone: 410-955-1725
1800 Orleans St.
Sheikh Zayed Tower
Baltimore, MD 21287
The Johns Hopkins Hospital (Main Entrance) - Google Maps

Background

Dr. Anna Durbin is an associate professor at the Johns Hopkins University School of Medicine. Her area of clinical expertise is infectious disease. 

Dr. Durbin earned her M.D. from Wayne State University School of Medicine. She completed her residency and performed a fellowship in infectious diseases at Detroit Medical Center.

She has expertise in the evaluation of live attenuated flavivirus vaccines, primary dengue and West Nile virus vaccines, and the early evaluation of malaria vaccines. She has served on national and international advisory boards and committees related to dengue and malaria vaccine safety. 

An important research interest of hers is studying the immunopathogenesis of dengue infection and disease. In addition to her clinical studies, her laboratory is also developing an animal model of dengue using rhesus macaques.

...read more

Titles

  • Joint Appointment in Medicine

Departments / Divisions

Centers & Institutes

Education

Degrees

  • MD; Wayne State University School Of Medicine (1987)

Residencies

  • Internal Medicine; Detroit Medical Center (1990)

Fellowships

  • Infectious Diseases; Detroit Medical Center (1999)

Board Certifications

  • American Board of Internal Medicine (Infectious Disease) (1994)
  • American Board of Internal Medicine (Internal Medicine) (1990)

Research & Publications

Research Summary

Dr. Durbin’s research involves the evaluation of experimental vaccines in human clinical trials. At the Center for Immunization Research, she and her team have conducted numerous clinical trials of many different pediatric and adult candidate vaccines. These trials have included vaccines against HIV, hepatitis C, human papilloma virus, influenza, rotavirus, respiratory syncytial virus, dengue virus and malaria. She is primarily interested in vaccines against dengue viruses and malaria, and has very active dengue and malaria vaccine programs at the Center for Immunization Research. They have conducted numerous Phase I live attenuated dengue vaccine trials with the ultimate goal of identifying suitable monovalent vaccine viruses for inclusion in a tetravalent dengue vaccine. In addition, they have conducted many Phase I malaria vaccine trials at their clinical site in Washington, DC. One of Dr. Durbin’s interests is studying the immunopathogenesis of dengue infection and disease. Her team hopes to better understand the viral, host and immunologic factors causing severe dengue illness by extensively characterizing the cellular and humoral responses of volunteers to live attenuated dengue virus vaccines. In addition to their clinical studies, Dr. Durbin’s laboratory is also developing an animal model of dengue using rhesus macaques.

Lab

Lab Website: Anna Durbin Lab

Clinical Trials

Selected Publications

Durbin AP, Whitehead SS. “Dengue vaccine candidates in development.” Curr Top Microbiol Immunol. 2010;338:129-43.

Ellis RD, Martin LB, Shaffer D, Long CA, Kazutoyo M, Fay MP, Narum DL, Zhu D, Mullen GE, Mahanty S, Miller LH, Durbin AP. “Phase 1 trial of the Plasmodium falciparum blood stage vaccine MSP142-C1/alhydrogel with and without CPG 7909 in malaria naïve adults.” PLos One. 2010;5(1):e8787.

Blaney JE, Jr., Durbin AP, Murphy BR and Whitehead SS. “Targeted mutagenesis as a rational approach to dengue virus vaccine development.” Curr Top Microbiol Immunol. 2010;338:145-58.

Wright PF, Durbin AP, Whitehead SS, Ikizler MR, Henderson S, Blaney JE, Thumar B, Ankrah S, Rock MT, McKinney BA, Murphy BR, and Schmidt AC. “Phase 1 trial of the dengue virus type 4 vaccine candidate rDEN4D30-4995 in healhty adult volunteers.” Am J Trop Med Hyg. 2009; 81(5):834-41.

Durbin AP, Whitehead SS. “Dengue vaccine candidates in development.” Curr Top Microbiol Immunol. 2010;338:129-43.

Academic Affiliations & Courses

Courses and Syllabi

  • Special Topics in Vaccine Science (223.867.01)
    Johns Hopkins Bloomberg School of Public Health
    2015 - 2016
  • Biologic Basis of Vaccine Development (223.689.01)
    Johns Hopkins Bloomberg School of Public Health
    2015 - 2016

Activities & Honors

Honors

  • NIH Director's Award, 2010
  • National Institutes of Health Merit Award, 2005
Is this you? Edit Profile
back to top button